Fluorine 18 MK 6240

Drug Profile

Fluorine 18 MK 6240

Alternative Names: [18F]MK 6240; [18F]MNI-946; [3H]MK 6240; [F-18]MK-6240; Fluorine-18-MK6240; MK-6240

Latest Information Update: 22 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Sharp & Dohme
  • Developer Cerveau Technologies; Janssen Pharmaceuticals; Merck Sharp & Dohme; Washington University School of Medicine
  • Class Imaging agents; Radiopharmaceuticals
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Alzheimer's disease
  • Research Neurodegenerative disorders

Most Recent Events

  • 16 Jan 2018 Cerveau Technologies and University of Pittsburgh enter into a research agreement for multiple projects involving Fluorine 18 MK 6240
  • 11 Jan 2018 Columbia University and National Institute on Aging plans the NOMEM-Tau phase II trial in Healthy volunteers in USA, in January 2018 (NCT03389100)
  • 19 Dec 2017 Cerveau Technologies and University of Washington enter into a research agreement for multiple projects involving Fluorine 18 MK 6240
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top